ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Randomized Trial"

  • Abstract Number: 1492 • ACR Convergence 2024

    Timing of SLEDAI-2K Item Improvements During the First Year of Intravenous Anifrolumab Treatment of Moderate to Severe SLE

    Edward Vital1, Richard Furie2, Eric Morand3, Ian Bruce4, Jacob Knagenhjelm5 and Catharina Lindholm6, 1Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom, Leeds, England, United Kingdom, 2Northwell Health, Manhasset, NY, 3School of Clinical Sciences, Monash University, Melbourne, Victoria, Australia, 4Centre for Musculoskeletal Research, The University of Manchester, Manchester, United Kingdom, 5BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden, 6BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden, Gothenburg, Sweden

    Background/Purpose: SLE is a chronic disease in which irreversible organ damage can accumulate over time; treatments associated with rapid responses in patients are therefore desirable.1…
  • Abstract Number: 1718 • ACR Convergence 2024

    Randomization to Holding versus Continuing (JAKi, IL17) and Autoimmune Patient Responses to COVID-19 Boosters: Results from the Covid-19 VaccinE Response in Rheumatology Patients (COVER) Study

    Amy Mudano1, Gary Cutter2, Emily Holladay3, Kevin Winthrop4, Ted Mikuls5, Geoffrey Thiele5, Mark Law5, Monique Bastidas6, Mike Zikry6, Kelly Chun6, Michael George7, Jayashree Sinha8, Naiara Alvarez9, John Tesser10 and Jeffrey Curtis11, and COVER Site Principal Investigator Group, 1Illumination Health, Hoover, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3University of Alabama at Birmingham, Edmond, OK, 4School of Medicine, Oregon Health and Science University, Portland, OR, 5University of Nebraska Medical Center, Omaha, NE, 6Labcorp, Calabasas, CA, 7University of Pennsylvania, Philadelphia, PA, 8self employed, Clovis, NM, 9Integrative Rheumatology of South Texas, McAllen, TX, 10Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, 11University of Alabama at Birmingham, Hoover, AL

    Background/Purpose: Best practice for the use of immunosuppression to optimize vaccine response remains uncertain. We conducted the Covid VaccinE Response (COVER) trial, a multicenter, randomized…
  • Abstract Number: 2341 • ACR Convergence 2024

    Influence of Patient Baseline Characteristics on Zasocitinib (TAK-279) Efficacy, a Selective Oral Tyrosine Kinase 2 Inhibitor: A Randomized Phase 2b Trial in Psoriatic Arthritis

    Lihi Eder1, Elena Muensterman2, Desiree van der Heijde3, Alan Kivitz4, Mona Trivedi5, Ting Hong5, Muhammad Rehman5, Haoling Weng6, Jingjing Chen5 and Xenofon Baraliakos7, 1University of Toronto, Women’s College Hospital and Department of Medicine, Toronto, ON, Canada, 2Takeda Development Center Americas, Cambridge, MA, 3Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, 4Altoona Center for Clinical Research, Duncansville, PA, 5Takeda Development Center Americas, Inc., Cambridge, MA, 6HW MedAdvice LLC, San Diego, CA, 7Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, Bochum, Germany

    Background/Purpose: Zasocitinib (TAK-279) is a potent, highly selective, oral allosteric tyrosine kinase 2 (TYK2) inhibitor. In a recent phase 2b trial in active psoriatic arthritis…
  • Abstract Number: 2672 • ACR Convergence 2024

    Prevention of the Development of Rheumatoid Arthritis by a 1-year Course of Methotrexate in ACPA-negative Arthralgia Patients at Increased Risk for Rheumatoid Arthritis: 4 Year Results of the TREAT EARLIER Trial

    Quirine Dumoulin1, Doortje Krijbolder2, Karen Visser3, Leroy Lard4 and Annette van der Helm-van Mil5, 1Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands, 2Leiden University Medical Centre, Leiden, Netherlands, 3Haga Hospital The Hague, Amsterdam, Netherlands, 4Haaglanden Medical Center The Hague, Leidschendam, Netherlands, 5LUMC, Leiden, Zuid-Holland, Netherlands

    Background/Purpose: Currently, prevention possibilities of developing ACPA-negative rheumatoid arthritis (RA) are unknown. Studying this is challenging because many ACPA-negative at-risk individuals have low risk of…
  • Abstract Number: 0858 • ACR Convergence 2024

    Baricitinib in Early Polymyalgia Rheumatica (BACHELOR Study)

    Alain SARAUX1, Guillermo CARVAJAL ALEGRIA2, Emmanuelle Dernis3, christian roux4, Christophe Richez5, Alice TISON6, Baptiste Quere7, Sandrine Jousse-Joulin8, Dewi Guellec7, Thierry Marhadou9, Patrice Kervarrec7, Divi Cornec10, Catherine Le Henaff7, Sandra Lesven7, nowak emmanuel7, Aghiles Souki7 and Valerie Devauchelle11, 1CHU Brest, Brest, France, 2CHRU de Tours, Tours, France, 3CH LE MANS, LE MANS, Pays de la Loire, France, 4rheumatology department, university Cote d'Azur, nice, France, 5Université de Bordeaux, Bordeaux, France, 6CHU de la Cavale Blanche, Brest, France, Brest, France, 7Centre Hospitalier Regional Universitaire (CHU) de Brest, Brest, France, 8cavale blanche hospital, brest, France, 9CHU Cavale Blanche, Brest, France, 10University of Brest, Brest, France, 11UBO, Brest, France

    Background/Purpose: Moderate glucocorticoids (GCs) improve nearly all cases of polymyalgia rheumatica (PMR) but related adverse events are common in senior patients.  The purpose of this…
  • Abstract Number: 1496 • ACR Convergence 2024

    Dysregulated Serum Cytokines in Association with Clinical Manifestations in Patients with Systemic Lupus Erythematosus

    Loqmane seridi1, Steven Leonardo2, Brittney Scott3, Robert Gordon1, cathye shu1, Kaiyin Fei1, Kim Lo3, Anne Stevens1 and Sheng Gao3, 1Janssen Research & Development, LLC, Spring House, PA, 2Janssen Research & Development, LLC, a Johnson & Johnson Company, Cambridge, MA, 3Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA

    Background/Purpose: SLE is a heterogeneous autoimmune disease affecting multiple organ systems, making clinical trial design challenging. Biomarkers that can identify patients with specific clinical manifestations…
  • Abstract Number: 1731 • ACR Convergence 2024

    Baricitinib in the Treatment of Adult Idiopathic Inflammatory Myopathy: A Randomized, Treatment Delayed-Start Clinical Trial

    hector Chinoy1, Ashma Krishan1, Yvonne Sylvestre1, James Lilleker2, Patrick Gordon3, Sarah Tansley4, Athiveeraramapandian Prabu5, Aamir Aslam6, Andrew Snedden7 and Janine Lamb8, 1The University of Manchester, Manchester, United Kingdom, 2Northern Care Alliance NHS Trust, Salford, United Kingdom, 3nhs, London, United Kingdom, 4University of Bath, Bath, United Kingdom, 5Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, United Kingdom, 6Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 7Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom, 8University of Manchester, UK, Manchester, United Kingdom

    Background/Purpose: The aim of the study was to assess the effects of baricitinib, a JAK1/2 inhibitor, following 24 weeks of active treatment on disease activity…
  • Abstract Number: 2352 • ACR Convergence 2024

    Bimekizumab Treatment Was Efficacious to 2 Years Regardless of Duration of axSpA Symptoms: Results from Two Phase 3 Studies

    Sofia Ramiro1, Fabian Proft2, Raj Sengupta3, Astrid van Tubergen4, Anna Molto5, Lianne S Gensler6, Mitsumasa Kishimoto7, Vanessa Taieb8, Diana Voiniciuc9, Ute Massow10 and Victoria Navarro Compán11, 1Leiden University Medical Center, Bunde, Netherlands, 2Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, 3Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 4Department of Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, 5Groupe Hospitalier Cochin, AP-HP, Paris, France, 6Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, 7Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, 8UCB Pharma, Colombes, France, 9UCB Pharma, Slough, United Kingdom, 10UCB Pharma, Monheim am Rhein, Germany, 11La Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Madrid, Spain

    Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, showed efficacy to Week (Wk) 52 in patients (pts) with…
  • Abstract Number: 2675 • ACR Convergence 2024

    Which Arthralgia Patients at Risk for RA Benefited from Treatment with Methotrexate?; Results from the TREAT EARLIER Trial

    Stijn Claassen1, Quirine Dumoulin2, Kasper Glas3, Esmeralda Molenaar4, Hanna van Steenbergen1 and Annette van der Helm-van Mil5, 1Leiden University Medical Center, Leiden, Netherlands, 2Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands, 3Reumazorg Zuid West Nederland, Goes, The Netherlands, Goes, Zeeland, Netherlands, 4Groene Hart Ziekenhuis, Gouda, The Netherlands, Gouda, Zuid-Holland, Netherlands, 5LUMC, Leiden, Zuid-Holland, Netherlands

    Background/Purpose: A one-year methotrexate treatment in CSA has been shown to induce sustained reduction in subclinical inflammation during 2-years follow-up. We aim to study if…
  • Abstract Number: 0217 • ACR Convergence 2024

    Understanding Treatment Goals and Factors Influencing Decisions About Clinical Trial Participation in Lupus Patients from Diverse Backgrounds

    Joy Buie1, Safoah Agyemang1 and Joan Merrill2, 1Lupus Foundation of America, Washington, DC, 2Oklahoma Medical Research Foundation, Oklahoma City 73104, OK

    Background/Purpose: With many emerging treatments in development for lupus, clinical trial recruitment has become increasingly difficult. Growing appreciation of patient input into trial design may be of …
  • Abstract Number: 1131 • ACR Convergence 2024

    Zasocitinib (TAK-279), a Selective Oral Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement in a Phase 2b Trial in Moderate-to-Severe Plaque Psoriasis

    Vivian Laquer1, Leon Kircik2, Neil Sadick3, Jamie Weisman4, Yiwei Zhao5, Jessamyn Blau5, Wenwen Zhang6, Jonathan Uy5, Warren Winkelman6 and Melinda Gooderham7, 1First OC Dermatology Research, Fountain Valley, CA, 2Icahn School of Medicine at Mount Sinai, New York, NY, 3Weill Cornell Medical College, New York, NY, 4Piedmont Atlanta, Atlanta, GA, 5Takeda Development Center Americas, Inc., Cambridge, MA, 6Takeda Development Center Americas, Inc., Cambridge, 7SKiN Centre for Dermatology and Probity Medical Research, Peterborough, ON, Canada

    Background/Purpose: Zasocitinib (TAK-279) is a highly selective, allosteric, oral inhibitor of tyrosine kinase 2 (TYK2). TYK2 mediates signaling from cytokines involved in the pathogenesis of…
  • Abstract Number: 1542 • ACR Convergence 2024

    Efficacy and Safety Results from a Phase 2 Trial of Daxdilimab in Patients with Systemic Lupus Erythematosus

    Arezou Khosroshahi1, Sarah Welsh2, Liangwei Wang2, David Larson2 and Nisha Jain2, 1Emory University, Atlanta, GA, 2Amgen, Inc., Rockville, MD

    Background/Purpose: SLE, an autoimmune disease affecting multiple organ systems, is characterized by periods of flares and remission. Type I interferon secreted at high levels by…
  • Abstract Number: 1735 • ACR Convergence 2024

    High-Intensity Interval Training Outperforms Moderate Exercise in Aerobic Capacity for Recent-Onset Idiopathic Inflammatory Myopathies: A Randomized Controlled Trial

    Kristofer Andreasson1, Cecilia Leijding1, Maryam Dastmalchi2, Antonella Notarnicola3, Stefano Gastaldello1, Heléne Sandlund2, Daniel Andersson4, Ingrid Lundberg5 and Helene Alexanderson2, 1Karolinska Institutet, Stockholm, Sweden, 2Karolinska University hospital, Stockholm, Sweden, 3Karolinska University Hospital and Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, 4Karolinska Institutet, Solna, Sweden, 5Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Exercise is a recognized adjunctive therapy for patients with idiopathic inflammatory myopathies (IIM), enhancing physical capacity and reducing inflammation. Hitherto, moderate-to-intensive exercise has been…
  • Abstract Number: 2353 • ACR Convergence 2024

    Effects of Guselkumab on cDAPSA Disease Activity State and Its Association with Long-Term Radiographic Progression in a Cohort of Patients with Moderately-Highly Active Psoriatic Arthritis: Post Hoc Analyses of Phase 3 Randomized Controlled Studies

    Philip Mease1, Alice Gottlieb2, Iain McInnes3, Natalie J. Shiff4, Toby Thomas5, Emmanouil Rampakakis6, Francois Nantel7, Frederic Lavie8 and Proton Rahman9, 1Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA, 2Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA, 3University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom, 4Janssen Scientific Affairs, LLC / University of Saskatchewan, Adjunct, Community Health and Epidemiology, Horsham, PA, 5Janssen Pharmaceuticals, Horsham, PA, 6McGill University, Department of Pediatrics / Scientific Affairs, JSS Medical Research Inc., Montreal, QC, Canada, 7Nantel MedSci Consult, Montreal, QC, Canada, 8Janssen Cilag Global Medical Affairs, Immunology Global Medical Affairs, Issy les Moulineaux, France, 9Memorial University of Newfoundland, Faculty of Medicine, Division of Rheumatology, St. John's, Canada

    Background/Purpose: In the Phase 3 DISCOVER (D)-1 and -2 studies, guselkumab (GUS; IL-23p19-subunit inhibitor) 100 mg every 4 weeks (Q4W) or Q8W significantly improved joint…
  • Abstract Number: 2686 • ACR Convergence 2024

    Dose Escalation Safety Study of Brentuximab Vedotin for Diffuse Cutaneous Systemic Sclerosis:Clinical Results and Mechanistic Analysis of Skin and Peripheral Blood Mononuclear Cells

    David Fox1, Laura Cooney2, Lia Stelzig3, Robert Lafyatis4, Johann Gudjonsson5, Lam Tsoi6, Maureen Mayes7, Ankoor Shah8, Suzanne Kafaja9, William Barry3, Ellen Goldmuntz10, Dawn Smilek11 and Dinesh Khanna6, 1University of Michigan, Dexter, MI, 2University of Michigan and Immune Tolerance Network, Ann Arbor, MI, 3Rho, Durham, NC, 4Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 5Department of Dermatology, University of Michigan, Ann Arbor, MI, 6University of Michigan, Ann Arbor, MI, 7UTHealth Houston Division of Rheumatology, Houston, TX, 8Duke University, Durham, NC, 9Division of Rheumatology, University of California, Los Angeles, Los Angeles, CA, 10Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, Rockville, MD, 11Immune Tolerance Network, UCSF, San Francisco, CA

    Background/Purpose: Brentuximab vedotin (ADCETRIS®) is a drug antibody conjugate targeting CD30 approved for treatment of Hodgkin’s lymphoma (HL) and other hematologic malignancies. Association of CD30…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • …
  • 19
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology